三生制药(01530.HK)今日盘中大跌5.1%,引发市场关注。根据公司最新公告,此次股价下跌主要与其向辉瑞发行新股有关。
公告显示,三生制药于7月24日与辉瑞达成协议,将向后者定向发行3114.25万股新股,发行价为每股25.2055港元,较协议签署日收盘价30.40港元折价约17.09%。此次发行将为三生制药募集约7.85亿港元资金。
此外,三生制药还宣布与辉瑞就PD-1/VEGF双特异性抗体(SSGJ-707)达成许可协议。该协议已于7月24日生效,标志着双方在创新药物研发领域的战略合作正式启动。尽管此次合作对三生制药长期发展有利,但短期内的股份稀释效应导致股价承压。投资者需密切关注公司后续在创新药领域的进展及其对业绩的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.